breast-darn-thermography-blog-ever-this-aint-your-mothers-breast-screening

THE BOOBY TRAP'S REFERENCES

Wendy Sellens

 

 "The Booby Trap - Estrogen makes you crazy, fat, old and triggers breast cancer," is a quick overview of our professional book "The Breast Thermography Revolution - Boot Camp for an Estrogen Free Life, which has more detailed information, over 450 breast thermograms, cancer statistics and breast cancer chronology, thermography basics, breast cancer facts/genetics etc, side effects of all estrogen therapies direct from manufacturer, issues with progesterone therapy, plus we debunk flax studies and show how they are manipulated, get our other book - coming in at 520 pages and weighing 2 lbs!

Below are the references and a chronology of breast cancer and estrogen.


References

 Intel

"About Breast Cancer." Susan G. Komen for the Cure Puget Sound. Puget Sound Affiliate of Susan G. Komen for the Cure, n.d. Web. <http://www.komenpugetsound.org/understanding-breast-cancer/about-breast-cancer/>.

Boschert, Sherry. "Teenage Menstruation: What's Normal and What's Not?." Internal Medicine News. 01 Feb 2009: n. page. Web.

"Breast cancer: Prevention and control." World Health Organization. World Health Organization. Web. <http://www.who.int/cancer/detection/breastcancer/en/index5.html>.

"Breast Cancer Statistics." Susan G. Komen for the Cure. Susan G. Komen for the Cure, n.d. Web. <http://ww5.komen.org/breastcancer/statistics.html>.

DeSantis, Carol. Breast Cancer Facts & Figures 2007-2008. 1st Ed. Atlanta, Ga.: American Cancer Society, 2007. Print.

DeSantis, Carol. Breast Cancer Facts & Figures 2009-2010. 1st Ed. Atlanta, Ga.: American Cancer Society, 2009. Print.

DeSantis, Carol. Breast Cancer Facts & Figures 2009-2010. 1st Ed. Atlanta, Ga.: American Cancer Society, 2009. Print.

DeSantis, Carol. Breast Cancer Facts & Figures 2009-2010. 1st Ed. Atlanta, Ga.: American Cancer Society, 2009. Print.

DeSantis, Carol. Breast Cancer Facts & Figures 2011-2012. 1st Ed. . Atlanta, Ga.: American Cancer Society, 2011. Print.

"Estimated Breast-Cancer Mortalities, Incidence, and I/M Ratios, U.S.A * ." CA - A Cancer Journal for Clinicians n.pag. American Cancer Society. Database.

"Fast Stats." Surveillance Epidemiology and End Results. National Cancer Institute, n.d. Web. <http://seer.cancer.gov/faststats>.

Forouzanfar, Mohammad. "Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis." Lancet. 378.9801 (2011): 1461-84. Print.

"Menstrual Cycle." Natural Family Planning Teachers Association of Ireland. Natural Family Planning Teachers Association of Ireland, n.d. Web. 

"Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign." Journal of the American Academy of Pediatrics. 118.5 (2006): 2245-2250. Web. <http://pediatrics.aappublications.org/content/118/5/2245.abstract?sid=72292d5a-a247-4ef9-8ba1-87c4035d586f>.

Nakamoto, Jon. "Menarche: Myths and variations in normal pubertal development." Western Journal of Medicine. 172.3 (2000): 182-185. Web.  <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1070801/>.

Powell, Alvin. "Breast cancer danger rising in developing countries." Harvard Gazette [Cambridge, Mass.] 16 April 2009, n. pag. Web.  <http://news.harvard.edu/gazette/story/2009/04/breast-cancer-danger-rising-in-developing-world/>.

Scowcroft, Henry. "Why are breast cancer rates increasing?." Cancer Research UK. Cancer Research UK, 04 Feb 2011. Web. <http://scienceblog.cancerresearchuk.org/2011/02/04/why-are-breast-cancer-rates-increasing/>.

Smigal, Carol. Breast Cancer Facts & Figures 2005-2006. 1st Ed. Atlanta, Ga.: American Cancer Society, 2005. Print.

Stewart, Sherri, Jessica King, et al. United States. Department of Health and Human Services. Cancer Mortality Surveillance - United States - 1990-2000. Washington, DC: U.S. Government Printing Office, 2004. Print.

Warren, Barbour, and Carol Devine. "Breast Cancer in Men." Program on Breast Cancer and Environmental Factors (2010): n.pag. Web. Cornell University, College of Veterinary Medicine. <http://ecommons.library.cornell.edu/handle/1813/14300>.

"What are the key statistics about breast cancer?" Surveillance Epidemiology and End Results. National Cancer Institute, n.d. Web. <http://seer.cancer.gov >.

"What Is Hormonal Therapy?." Breastcancer.org. N.p., 17 Sep 2012. Web. <http://www.breastcancer.org/treatment/hormonal/what_is>.

Physiology

Netter, Frank. Ciba Collection of Medical Illustrations - Reproductive. Washington, DC: Library of Congress, 1975. Print.

Chemical Warfare

Anderson, G.L., M. Limacher, A.R. Assaf, et al. "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy." Journal of the American Medical Association. 291.14 (2004): 1701-1712. Web. <http://jama.jamanetwork.com/article.aspx?articleid=198540>.

Chilvers, CED, and JM Deacon. "Oral contraceptives and breast cancer." British Journal of Cancer. 61. (1990): 1-4. Print.

Chilvers, CED, and SJ Smith. "The effect of patterns of oral contraceptive use on breast cancer risk in young women. ." British Journal of Cancer. 69.5 (1994): 922-923. Web. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968892/>.

Chlebowski, Rowan, Garnet Anderson, Margery Gass, et al. "Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women ." Journal of the American Medical Association. 304.15 (2010): 1684-1692. Web.  <http://jama.jamanetwork.com/article.aspx?articleid=186747>.

Collins, John, Jennifer Blake, et al. "Breast cancer risk with postmenopausal hormonal treatment." Human Reproduction Update. 11.6 (2005): 545-560. Web.   <http://humupd.oxfordjournals.org/gca?gca=humupd;11/6/545&submit=Go&allch=&action=Get All Checked Abstracts>.

Elstein, M., and K. Ferrer. "The Effect Of A Copper-Releasing Intrauterine Device On Sperm Penetration In Human Cervical Mucus In Vitro." Reproduction32, no. 1 (1973): 109-11. doi:10.1530/jrf.0.0320109.

Heiss, Gerardo, Robert Wallace, Garnet Anderson, et al. "Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin ." Journal of the American Medical Association. 299.9 (2008): 1036-1045. Web. 14 Mar. 2013. <http://jama.jamanetwork.com/article.aspx?articleid=1108397>.

Hulley, S, D Grady, et al. "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. ." Journal of American Medical Association. 280.7 (1998): 605-613; 671-672. Print.

"IUDs Block Fertilization." United Nations. Published Winter 1996. http://www.un.org/popin/popis/journals/network/network162/blck162.html.

Lacey, James, Pamela Mink, Jay Lubin, et al. "Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer ." Journal of the American Medical Association. 288.20 (2002): 2544. Web. <http://jama.jamanetwork.com/article.aspx?articleid=195119>.

Lee, John. What your doctor may not tell you about menopause. New York, NY: Grand Central Publishing, 1996. Print.

"Oral Contraceptives and Cancer Risk." National Cancer Institute. National Institutes of Health, 21 Mar 2012. Web. <http://www.cancer.gov/cancertopics/factsheet/Risk/oral-contraceptives>.

"Overview: Breast Cancer and the Pill." The Polycarp Research Institute. The Polycarp Research Institute. Web. <http://www.polycarp.org/overviewbreastcanceroralcontraceptives.htm>.

Pike, MC, BE Henderson, JT Casagrande, et al. "Oral Contraceptive Use and Early Abortion as Risk Factors for Breast Cancer in Young Women.” British Journal of Cancer. 43.72 (1981): n. page. Print.

Rossouw, JE, GL Anderson, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results ." Journal of American Medical Association. 288.3 (2002): 321-333. Print.

"The Estrogen-Plus-Progestin Study." Women's Health Initiative. National Institutes of Health. Web. <http://www.nhlbi.nih.gov/whi/estro_pro.htm>.

What are the risk factors for breast cancer?. (2013, February 26). Retrieved from http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors

Biological Warfare

Almada, Anthony. "SDG precision standardized Flaxseed Extract Scientific Research Monograph." Brevail. 2003: n. page. Print.

Bergman Jungeström, Malin , Lilian Thompson, and Charlotta Dabrosin. "Flaxseed and Its Lignans Inhibit Estradiol-Induced Growth, Angiogenesis, and Secretion of Vascular Endothelial Growth Factor in Human Breast Cancer Xenografts In vivo." Clinical Cancer Research. 13.3 (2007): 1061-1067. Web. <http://clincancerres.aacrjournals.org/content/13/3/1061.long>.

Daniel, Kaayla. The Whole Soy Story - the dark side of America's favorite health food . Washington, DC: New Trends Publishing, 2005. Print.

Duffy , Christine, Kimberly Perez, and Ann Partridge. "Implications of Phytoestrogen Intake for Breast Cancer ." Clinical Cancer Research. 57. (2007): 260-277. Print.

Fallon, Sally, and Mary Enig. "Cinderella's Dark Side."Nexus. Apr 2000: n. page. Web. <http://www.mercola.com/article/soy/avoid_soy3.htm>.

Iguchi, Taisen, and Tomomi Sato. "Endocrine Disruption and Developmental Abnormalities of Female Reproduction." American Zoologist. 40.3 (2000): 402-411. Print.

Kuhnle, Gunter G. C., Caterina Dell’Aquila, Sue M. Aspinall, Shirley A. Runswick, Angela A. Mulligan, and Sheila A. Bingham. "Phytoestrogen Content of Foods of Animal Origin: Dairy Products, Eggs, Meat, Fish, and Seafood." Journal of Agricultural and Food Chemistry56, no. 21 (2008): 10099-0104. doi:10.1021/jf801344x.

Lee, John, Zava, David, and Virginia Hopkins. What your doctor may not tell you about breast cancer. New York : Warner Books, Inc., 2005. Print.

Lee, John, and Virginia Hopkins. What your doctor may not tell you about menopause. New York : Warner Books, Inc., 1996. Print.

Saika, Kumiko, and Tomotaka Sobue. "Epidemiology of Breast Cancer in Japan and the US." Japan Medical Association Journal. 52.1 (2009): 39-44. Print.

Selchell, KDR. Discovery and Importance of Lignans. 92-93. Print. [Unable to further source this reference.]

Thompson, Lilian U., Beatrice A. Boucher, Zhen Liu, Michelle Cotterchio, and Nancy Kreiger. "Phytoestrogen Content of Foods Consumed in Canada, Including Isoflavones, Lignans, and Coumestan." Nutrition and Cancer54, no. 2 (2006): 184-201. doi:10.1207/s15327914nc5402_5.

Valentzis, LS, MM Cantwell, C Cardwell, et al. "Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies." British Journal of Cancer. 100.9 (2009): 1492-1498. Print.

Zava, David T., Charles M. Dollbaum, and Marilyn Blen. "Estrogen and Progestin Bioactivity of Foods, Herbs, and Spices." Hypertension (High Blood Pressure). Accessed September 03, 2018. http://www.cancersupportivecare.com/estrogenherb.html.

 Ecoterrorism

Arnold, SF, Peter Vonier, et al. "In vitro synergistic interaction of alligator and human estrogen receptors with combinations of environmental chemicals." Environmental Health Perspectives. 105. (1997): 615-618. Print.

Colborn, Theo. "TEDX The Endocrine Disruption Exchange." Overdose: How Drugs and Chemicals in Water and the Environment are Harming Fish and Wildlife. Committee on Natural Resources. 1324 Longworth House Office Building, Washington, DC. 9 Jun 2009. Address.

"Effects of Pollutants on the Reproductive health of Male Vertebrae Wildlife- Males Under Threat." Chemtrust. 2007-2009: n. page. Web. <http://www.chemtrust.org.uk/documents/Male Wildlife Under Threat 2008 full report.pdf>.

"Endocrine Disruptor Screening Program."Environmental Protection Agency. Environmental Protection Agency, 11 August 2011. Web. <http://www.epa.gov/endo/pubs/edspoverview/primer.htm>.

Golden, R, J Gandy, and G Vollmer. "A review of the endocrine activity of parabens and implications for potential risks to human health." Critical reviews in toxicology. 35.5 (2005): 435-458. Web. <http://www.ncbi.nlm.nih.gov/pubmed/16097138>.

Long, M, A Stronati, et al. "Relation between serum xenobiotic-induced receptor activities and sperm DNA damage and sperm apoptotic markers in European and Inuit populations." Reproduction. 133.2 (2007): 517-530. Print.

McLachlan, John, and Steven Arnold. "Environmental Estrogens." American Scientist. 84. (1996): 452-461. Print.

Newbold, RR, RB Hanson, et al. "Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol." Carcinogenesis. 19.9 (1998): 1655-1663. Web. <http://carcin.oxfordjournals.org/content/19/9/1655.short>.

"PANNA: New Evidence That Endocrine Disruptors Block Sperm Function." Pesticide Action Network Updates Service. (2002): n. page. Web. <http://www.panna.org/legacy/panups/panup_20020802.dv.html>.

Steinmetz, Rosemary, Natasha Mitchner, et al. "The Xenoestrogen Bisphenol A Induces Growth, Differentiation, and c-fos Gene Expression in the Female Reproductive Tract." Endocrinology. 139.6 (1998): 2741-2747. Web. <http://endo.endojournals.org/content/139/6/2741.full.pdf>.

Breast Canswers to Estrogen Lies

Ahmed, SA, BD Hissong, et al. "Gender and Risk of Autoimmune Diseases: Possible Role of Estrogenic Compounds." Environmental Health Perspectives. 107.5 (1999): 681-686. Print.

Daniel, Kaayla. The Whole Soy Story - the dark side of America's favorite health food . Washington, DC: New Trends Publishing, 2005. Print.

Duffy , Christine, Kimberly Perez, and Ann Partridge. "Implications of Phytoestrogen Intake for Breast Cancer ." Clinical Cancer Research. 57. (2007): 260-277. Print.

Fallon, Sally, and Mary Enig. "Cinderella's Dark Side."Nexus. Apr 2000: n. page. Web. <http://www.mercola.com/article/soy/avoid_soy3.htm>.

Gerson, Joel. Milad'ys Standard Textbook for Professional Estheticians . 8. Albany, NY: Delmar, 1998. 77. Print.

Graham, J Dinny, and Christine Clarke. "Physiological Action of Progesterone in Target Tissues."Endocrine Reviews. 18.4 (1997): 502. Web. 25 Mar. 2013. <http://edrv.endojournals.org/content/18/4/502.abstract>.

Haapasaari, KM, T Raudaskoski, et al. "Systemic therapy with estrogen or estrogen with progestin has no effect on skin collagen in postmenopausal women."Maturitas. 27.2 (1997): 153-162. Print.

Harvey,  et al. "Cholesterol and health Uncovering the truth about America’s demonized nutrient."Biochemistry. (2005): 235-238. Print.

Heiss, Gerardo, Wallace, Robert, et al. “Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin.” Journal of the American Medical Association. 2008; 299(9): 1036-1045

Hulley, Stephen, Deborah Grady, et al. "Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women ." Journal of the American Medical Association. 280.7 (1998): 605-. Web. <http://jama.jamanetwork.com/article.aspx?articleid=187879>.

Iguchi, Taisen, and Tomomi Sato. "Endocrine Disruption and Developmental Abnormalities of Female Reproduction." American Zoologist. 40.3 (2000): 402-411. Print.

Jick, H, B Dinan, and KJ Rothman. "Oral contraceptives and nonfatal myocardial infarction." Journal of the American Medical Association. 239.14 (1978): 1403-1406. Print.

Lee, John, and Virginia Hopkins. What your doctor may not tell you about menopause. New York : Warner Books, Inc., 1996. Print.

Lee, John, and David Zava. What your doctor may not tell you about breast cancer. New York : Warner Books, Inc., 2002. Print.

Maheux, R, F Naud, M Rioux, et al. "A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness."American Journal of Obstetrics and Gynecology. 170.2 (1994): 642-649. Print.

Netter, Frank. Ciba Collection of Medical Illustrations - Reproductive. Washington, DC: Library of Congress, 1975. Print.

Nicodemus, Kristin, Aaron Folsom, and Kristin Anderson. "Menstrual History and Risk of Hip Fractures in Postmenopausal Women The Iowa Women's Health Study." Amrican Journal of Epidemiology. 153.3 (2001): 251-255. Print.

Patriarca, MT, KZ Goldman, JM Dos Santos, et al. "Effects of topical estradiol on the facial skin collagen of postmenopausal women under oral hormone therapy: a pilot study." Eur J Obstet Gynecol Reprod Biol. 130.2 (2006): 202-205. Print.

Piérard-Franchimont, C, C Letawe, et al. "Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study." Maturitas. 22.2 (1995): 151-154. Web. <http://www.maturitas.org/article/0378-5122(95)00924-A/abstract>.

Prior, JC. "Progesterone as a bone-trophic hormone."Endocrine Reviews. 11.2 (1990): 386-398. Print.

Rickard, David, Urszula Iwaniec, Glenda Evans, et al. "Bone Growth and Turnover in Progesterone Receptor Knockout Mice." Endocrinology. 149.5 (2008): 2383–2390. Print.

Rinzler, Carol Ann. Estrogen and Breast Cancer: A Warning to Women. New York: Macmillan Publishing Company.1993. Print

Rossouw, JE, GL Anderson, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.." Journal of the American Medical Association. 288.3 (2002): 321-333. Web. <http://jama.jamanetwork.com/article.aspx?articleid=195120>.

Saika, Kumiko, and Tomotaka Sobue. "Epidemiology of Breast Cancer in Japan and the US." Japan Medical Association Journal. 52.1 (2009): 39-44. Print.

Schmidt, JB, M Binder, et al. "Treatment of skin aging with topical estrogens." International Journal of Dermatology. 35.9 (1996): 669-674. Print.

Selchell, KDR. Discovery and Importance of Lignans. 92-93. Print. [Unable to further source this reference.]

Son, ED, and JY Lee. "Topical application of 17beta-estradiol increases extracellular matrix protein synthesis by stimulating tgf-Beta signaling in aged human skin in vivo." Journal of Investigative Dermatology. 124.6 (2005): 1149-1161. Web. <http://www.nature.com/jid/journal/v124/n6/full/5602843a.html>.

"Uterus." The Free Dictionary. Dorland's Medical Dictionary for Health Consumers. Web. <http://medical-dictionary.thefreedictionary.com/uterus>.

"Vagina." The Free Dictionary. Dorland's Medical Dictionary for Health Consumers. Web. <http://medical-dictionary.thefreedictionary.com/vagina>.

Varila, E, I Rantala, et al. "The effect of topical oestradiol on skin collagen of postmenopausal women." British Journal of Obstetrical Gynaecology. 102.12 (1995): 985-989. Print.

Valentzis, LS, MM Cantwell, C Cardwell, et al. "Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies." British Journal of Cancer. 100.9 (2009): 1492-1498. Print.

Supplements

Baggott, JE, RA Oster, and T Tamura. "Meta-analysis of cancer risk in folic acid supplementation trials." Cancer Epidemiology. 36.1 (2012): 78-81. Print.

Brody, Jane. "Puzzle in a Bottle -- A special report; In Vitamin Mania, Millions Take a Gamble on Health."New York Times [New York] 26 October 1997, Health. Print.

Carmel, Ralph. "Is testing for clinical cobalamin deficiency truly unreliable?." Journal of the American Society of Hematology. 106.3 (2005): 1136-1138. Web. 25 Mar. 2013. <http://bloodjournal.hematologylibrary.org/content/106/3/1136.2.full>.

Klein, Eric, Ian Thompson, et al. "Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial." Journal of the American Medical Association. 306.14 (2011): 1549-1556. Web. <http://jama.jamanetwork.com/article.aspx?articleid=1104493>.

Larsson, SC, A Akesson, L Bergkvist, and A Wolk. "1.Multivitamin Use and Breast Cancer Incidence in a Prospective Cohort of Swedish Women."American Journal of Clinical Nutrition. 91.5 (2010): 1268-1272. Print.

Lawson, KA, ME Wright, et al. "Multivitamin Use and Risk of Prostate Cancer in the National Institutes of Health–AARP Diet and Health Study." Journal of the National Cancer Institute. 99.10 (2007): 754-764. Print.

Omenn, Gilbert, Gary Goodman, et al. "Full Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease." New England Journal of Medicine. 334. (1996): 1150-1155. Web. 25 Mar. 2013. <http://www.nejm.org/doi/full/10.1056/NEJM199605023341802>.

Patterson, Ruth. Functional Foods and Nutraceuticals. June 2003: n. page. Print. [Further source information is not available.]

"The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers." New England Journal of Medicine. 330.15 (1994): 1029-1035. Web. <http://atbcstudy.cancer.gov/pdfs/atbc33010291994.pdf>.

"What are the risk factors for breast cancer?." American Cancer Society. American Cancer Society, 26 Feb 2013. Web. <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors>.

 Progesterone

Hobbins, William, and Joseph Riina. "Double-Blind Study of Effectiveness Transcutaneous Progesterone in Fibrocystic Breast Conditions Monitored by Thermography." [Unk]. (1986): n. page. Print.

Lee, John, and Virginia Hopkins. What your doctor may not tell you about menopause. New York : Warner Books, Inc., 1996. Print.

Lee, John, and David Zava. What your doctor may not tell you about breast cancer. New York : Warner Books, Inc., 2002. Print.

Netter, Frank. Ciba Collection of Medical Illustrations - Reproductive. Washington, DC: Library of Congress, 1975. Print.

                                                 

Breast Cancer

"Breast Cancer Types." National Breast Cancer Foundation, Inc.. National Breast Cancer Foundation, Inc.. Web. <http://www.nationalbreastcancer.org/types-of-breast-cancer>.

"Breast Cancer Types: What Your Type Means." Mayo Clinic. Mayo Clinic, 02 Oct 2012. Web. <http://www.mayoclinic.com/health/breast-cancer/HQ00348>.

Cooke, Robert. Dr. Folkman’s War: Angiogenesis and the struggle to defeat cancer . 1st Ed. . New York: Random House, 2001. Print.

Gonzalez, Nicholas, and Linda Isaacs. The Trophoblast and the Origins of Cancer: One solution to the medical enigma of our time. 1st Ed. New York: New Spring Press, 2009. Print.

"What are the risk factors for breast cancer?." American Cancer Society. American Cancer Society, 26 Feb 2013. Web. <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-risk-factors>.

Certified Breast Thermography Survival Guide

For more breast thermography studies, around 1,100, please visit the research page of our website: womensacademyofbreastthermography.com

Gros, C, Gautherie, M. "Breast Thermography and Cancer Risk Prediction". Cancer 45:51-56 1980.

Haberman J, Goin J, Love T, Ohnsorg F, Aggarwal R. Breast cancer detection by absolute temperature thermography and computer techniques. In: Ring EFJ Phillips B eds. Recent Advances in Medical Thermology. Plenum Press, New York. 1984; pp. 557-569. [#877]

Hobbins, W.B. To Mammogram or Not - 5 years Practical Experience”

    Presented:   Wisconsin Surgical Society Milwaukee, WI, 1969

Hobbins, W.B. Seven Year Mammography Survey in Private Practice.

    Presented:   Wisconsin Surgical Society Door County, WI, 1971

11th Annual Early Breast Cancer Detection San Diego, CA, 1971

 Non-Mutilating Treastment for Bresat Cancer Strasbourg, France, 1972

Hobbins, W.B. Thermography in General Surgery Practice, Proceedings, American Thermographic Society, AGA, 1973

Hobbins. W. B. Mass Breast Cancer Screening by Thermography (1,100 women in 53 hours).

   Presented:    First European Thermographic Society Meeting Amsterdam, Netherlands, 1974   

                        American Thermographic Society Chicago, IL 1974

Hobbins, W.B. What Is a Day of Life Worth, RN Magazine, April, 1975

Hobbins. W.B. Mass Breast Cancer Screening with Thermography 25,000 cases.

   Presented:    American Thermographic Society Atalnta, GA 1975

                        Wisconsin Surgical Society Telemark WI 1975

Hobbins, W.B. Mass Breast Cancer Screening with Thermography, Applied Radiology, November-December 1976 5:57-62

Hobbins, W.B. Experiences with Thermographic Breast Cancer Screening in the State of Wisconsin, Proceedings, Breast Disease in Gynecological and Medical Primary Care Practice, pp. 267-281, April, 1977

Hobbins, W.B. Thermography, Highest Risk Marker in Breast Cancer, Proceedings, Gynecological Society for the Study of Breast Disease, pp. 267-282;59, 1977.

   Presented:    3rd International Symposium on Detection and Prevention of Cancer New York, NY, 1976.

                        American Thermographic Society Washington, D.C., 1976

                        The Canadian Thermographic Society Annual Meeting Montreal, Quebec, Canada, 1976.

                        The Second Annual Mid-American Breast Cancer Symposium Madison, WI,

1976

                        Gynecological Society for Study of Breast Diseases Washington, D.C., 1977

                        American Thermographic Society Boston, MA, 1978

                        French Thermographic Society Lyon, France, 1980

Hobbins, W.B. Who Has Breast Cancer? Lets Find Out, Clinical Medical, December 1977

Hobbins, W.B. Thermography – The Decision Maker

   Presented:    The American Gynecological Society for the Study of Breast Disease – Washington, D.C. April 1977

Hobbins, W.B. A Community Screening for Breast Cacner with Physical Exam and Thermography. Proceedings-Breast Disease in Gynecological and Medial Preamry Care Practice, April, 1977

   Presented:    American Thermographic Society Boston, MA, 1988

Hobbins, W.B. Thermal Signal in Breast Disease Sympathetic Nervous Infulence.

   Presented: American Thermographic Society Boston, MA, 1977

 Hobbins, W.B. Thermography, Highest Risk Marker (Mobile Mass Breast Cancer Screening). Medical Thermology, 1978

Hobbins, W.B. Mobile Mass Breast Cancer Screening; Thermography; Highest Risk Marker, Medical Thermography, European Press, Ghent, Belgium, pp. 61-67, 1978

Hobbins, W.B. Thermography and Pain, Medical Thermography, European Press, Ghent, Belgium, pp. 273-274, 1978

Hobbins, W.B. Thermography and Assessment of Breast Cancer (letter), JAMA 242:2761, 1979

Hobbins, W.B. B.J. King, Report of Thermographic Breast Biopsy Correlation ACTA Thermographica, Vol. 5, No. 1, pp.43-45, 1980

Hobbins, W.B. Comparison of Telethermography and Contact Thermography in Breast Thermal Examinations, ACTA Thermographica, Vol. 5, No. 1, pp. 51-53, 1980

   Presented:    European Thermographic Society Barcelona, Spain, 1978

                        Society for Study of Breast Disease Boston, MA 1979.

Hobbins, W.B. Thermography: highest risk marker. Presented, 8th Seminaire de Telethermographie, Lyon, June 26-28 (abstract). Acta Thermographica 1980; 5(3) 153.

Hobbins, W.B. Report of Thermographic Breast Biopsy Correlation. ACTA Thermographica, 1980

Hobbins, W.B. Significance of an Isolated Abnormal Colorgram, La Nouvelle Presse Medicale, Vol. 10, No. 38, pp. 3153-3155, 1981

   Presented:    Hungarian Medical Society Sarasota, FL, October 1981

                        American Thermographic Society Washington, D.C. May 1982

                        Fourth Symposium on Thermogrammatry Budapest, Hungary, March, 1983                      

Hobbins, W.B.  The Physiology of the Breast by Cholesteric Plate Analysis, in Gordon F. Schwartz and Douglas Marchant (eds), Breast Disease Diagnosis and Treatment, Elsevier/North-Holland, New York, pp. 87-98, 1981

   Presented: Society for Study of Breast Disease Philadelphia, PA, 1980

                        Association for the Advancement of Medical Instrumentation San Francisco, CA, 1980

                        4th International Symposium in Detection and Prevention of Cacner London, England 1980.

Hobbins, W.B. A New Beginning for Thermography, RNM Images, pp. 43-45, October 1982

Hobbins, W.B.  Thermography and Pain, in Michel Gautherie and Ernest Albert (eds), Biomedical Thermology, Alan R. Liss, Inc. New York, pp. 361-375, 1982

Hobbins, W.B. New Horizons in Thermography, Far East Health, January 1983

Hobbins, W.B. Thermography of the Breast Revisited 1982, Modern Medicine of Canada, March, 1983

Hobbins, W.B. Thermography (letter), CA, 372-376;33, 1983

Hobbins, W.B. The Combined Use of Thermography & Ultrasonography, in Jack Jellins and Toshiji Kobayashi (eds), Ultrasonic Examinations of the Breast, pp. 335-339, June, 1983

Hobbins, W.B. Thermography of the Breast A Skin Organ in Harry Rein (ed), The Primer on Thermography, pp 37, July, 1983

Hobbins, W.B. Thermography of the Breast A Skin Organ, in Gautherie M, Albert E, Keith L et al., Thermal Assessment of Breast Health. Chapter 5. MTP Press, Ltd. Lancaster, England, pp 37-48, July 1984

   Presented:    Argentinean Society of Mastology Buenos Aires, Argentina, April 1984.

                        Chilean Thermography Society Santiago, Chili, April 1984

Hobbins, W.B. Multimodality thermography’s role in ultrasound breast.  In Gautherie M, Albert E, Keith L et al., Thermal Assessment of Breast Health. Chapter 23. MTP Press, Ltd. Lancaster, England, pp 235-240, July 1984.

Hobbins, W.B., Abplanalp K, Barnes C, Miner S. Analysis of thermal class TH 5 examination in 37, 050 breast thermograms. In Gautherie M, Albert E, Keith L et al., Thermal Assessment of Breast Health. Chapter 25. MTP Press, Ltd. Lancaster, England, pp 249-255, July 1984.

Hobbin, W.B. Thermography + ultrasonography. In: Abernathy M, Uematsu S eds. Medical Thermology. Amer. Acad. of Thermology, Washington, D.C. 1986; pp. 246-249.

Hobbins, W.B., Abplanalp K, Barnes C, Miner S. Analysis of thermal class TH 5 examination in 37, 050 breast thermograms. In: Abernathy M, Uematsu S eds. Medical Thermology. Amer. Acad. of Thermology, Washington, D.C. 1986; pp. 250-255.

Presented:       International Conference on Thermal Assessment of Breast Health Washington, D.C. July, 1983

                        American Academy of Thermology Johns Hopkins School of Medicine, October, 1983.

                        American academy of Thermology 14th Annual Meeting Crystal City VA May/June, 1985

Hobbins, W.B. Thermography and Ultrasonography. Medical Thermology, 1986

   Presented:    Third International Congress on the Ultrasonic Examination of the Bresat Tokyo, Japan, June 1983

                        International Conference on Thermal Assessment of Breast Health Washington, D.C. July 1983

Hobbins, W.B. Double Blind Study of Effectiveness Transcurtaneous Progesterone in Fibrocystic Breast Conditions Monitored by Thermography.

   Presented:    Breast Diseases IV International Congress of Senology Paris, France, September, 1986

Jiang LJ, Ng FY et al "A Perspective on Medical Infrared Imaging". J Med Technol 2005 Nov-Dec;29(6):257-67

Lawson RN. Implication of surface temperatures in the diagnosis of breast cancer. Canadian Medical Association Journal 1956; 75-309. [#144].

Lawson RN. Thermography- a new tool in the investigation of breast lesions. (Reprinted in THERMOLOGY, 1(2): 115-119, 1985). Canadian Services Medical Journal 1957; 13:517-524. [#72].

Lawson RN, Chughtai MS. Breast cancer and body termperature. Can Med Assoc J 1963; 88:68-70. [#1437].

Lawson RN, et al. Breast cacner and heptaldehyde (preliminary report). Can Med Assoc J 1956; 75: 486. [#1440].

Spitalier, H., Giraud, D. et al. "Does Infrared Thermography Truly Have a Role in Present Day Breast Cancer Management?" Biomedical Thermology pp.269-278, 1982

Stark. A., Way, S. "The Screening of Well Women for the Early Detection of Breast Cancer Using Clinical Examination with Thermography and Mammography". Cancer 33: 1671-1679.

Y.R. Parisky, A. Sardi, R. Hamm, K. Hughes, L. Esserman, S. Rust, K.Callahan, "Efficacy of Computerized Infrared Imaging Analysis to Evaluate Mammographically Suspicious Lesions". AJR:180, January 2003

Articles on breast thermography research:

"Beyond Mammography - An Examination of Breast Thermography" by Len Saputo, M.D., Townsend Letter for Doctors and Patients, June 2004

"Efficacy of Computerized Infrared Imaging Analysis to Evaluate Mammographyically Suspicious Lesions" American Journal of Radiology, January 2003

"Infrared Imaging of the Breast" The Breast Journal, July/August 1998, Volume 4, Number 4 

"What You Should Know About Breast Thermography" by Len Saputo, M.D.

"Factors likely to Effect the Efficacy of Mammography" Journal of the National Cancer Institute Volume 91, Number 10, May 19, 1999

"Breast Cancer Detection Demonstration Project" Cancer, 1982, Volume 32, Pages 194-225

"Breast Masses: Mammographic Evaluation" Radiology, 1989, Pages 173-303

"MRI of the Breast: state of the art" European Radiology, Volume 8, Number 5, June 1998

"Comparison of FDG-PET and dynamic contrast enhanced MRI" The Breast, Volume 12, Issue 1, February 2003, Pages 17-22

Breast Cancer Boot Camp

Acupuncture: Review and Analysis of Reports on Controlled Clinical Trials. Geneva: World Health Organization, 202. Print.

Anna L. Choi, Guifan Sun, et al. “Developmental Fluoride Neurotoxicity: A Systematic Review and Meta-Analysis.” Environ Health Perspect. 2012 October; 120(10): 1362–1368.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491930/.>

Atkins, Robert C. Dr. Atkins New Diet Revolution. New York: Harper, 2008.

Bernard, Alfred, Marc Nickmilder, Catherine Voisin, and Antonia Sardella. "Impact of Chlorinated Swimming Pool Attendance on the Respiratory Health of Adolescents." Pediatrics. 124.4 (2009): 110-1118. Print. <http://pediatrics.aappublications.org/content/124/4/1110.abstract>.

Carton, Robert. Interview by Andrew Saul. 2006. doctoryourself.com. . Web. . http://www.doctoryourself.com/carton.html.

"Flouride." Sail Home. N.p.. Web. <http://www.sailhome.org/Concerns/BodyBurden/Burdens/Fluoride.html>.

Garg, Vinod Kumar and Singh, Bhupinder. “Fluoride in Drinking Water and Fluorosis.” Feb. 2007 <http://www.eco-web.com/edi/070207.html.>

Harvey,  et al. "Cholesterol and health Uncovering the truth about America’s demonized nutrient."Biochemistry. (2005): 235-238. Print.

HB 1416-Local – Final Version  s 1723  http://www.gencourt.state.nh.us/legislation/2012/HB1416.html  (25 April 2012)

Kuhnle, Gunter G. C., Caterina Dell’Aquila, Sue M. Aspinall, Shirley A. Runswick, Angela A. Mulligan, and Sheila A. Bingham. "Phytoestrogen Content of Foods of Animal Origin: Dairy Products, Eggs, Meat, Fish, and Seafood." Journal of Agricultural and Food Chemistry56, no. 21 (2008): 10099-0104. doi:10.1021/jf801344x.

"Lard Is the New Coconut Oil." Return to Now. May 14, 2018. Accessed September 26,2017. http://returntonow.net/2017/09/26/lard-new-coconut-oil/.

Lee, John, and Virginia Hopkins. What your doctor may not tell you about menopause. New York : Warner Books, Inc., 1996. Print.

Lee, John, and David Zava. What your doctor may not tell you about breast cancer. New York : Warner Books, Inc., 2002. Print.

Levy, SM, B Broffitt, et al. "Associations between fluorosis of permanent incisors and fluoride intake from infant formula, other dietary sources and dentifrice during early childhood." Journal of the American Dental Association. 141.10 (2010): 1190-1201. Print.

Lundell, Dwight. "Heart Surgeon Speaks Out On What Really Causes Heart Disease." Sign of the Times. Quantum Future Group, 01 Mar 2012. Web. <http://www.sott.net>.

Masterjohn, Chris. "Synthesis of Steroid Hormones From Cholesterol." Cholesterol and Health. N.p., 02 September 2005. Web. <http://www.cholesterol-and-health.com/Steroid-Hormones.html>.

"Milk Fat Built for Digestion." International Milk Genomics Consortium. Accessed September 03, 2017. http://milkgenomics.org/article/milk-fat-built-digestion/.

Moritz, Andreas. Heal Yourself with Sunlight. U.S.: Ener-chi Wellness Press, 2010.

Ober, Clinton, Stephen T. Sinatra, and Martin Zucker. Earthing: The Most Important Health Discovery Ever? Sydney, N.S.W.: Read How You Want, 2014.

"Omega-3 Fatty Acids: Fact Sheet." WebMD. N.p., 30 Mar 2011. Web. <http://www.webmd.com/healthy-aging/omega-3-fatty-acids-fact-sheet>.

"Top 11 compounds in US drinking water ." Newscientist. Newscientist, 12 Jan 2009. Web. <http://www.newscientist.com/article/dn16397-top-11-compounds-in-us-drinking-water.html>.

San-Xiang Wang,1 Zheng-Hui Wang, et al. “Arsenic and Fluoride Exposure in Drinking Water: Children’s IQ and Growth in Shanyin County, Shanxi Province, China.” Environ Health Perspect. 2007 April; 115(4): 643–647. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852689/>.

Sisson, Mark, and Mark Sisson. The New Primal Blueprint: Reprogram Your Genes for Effortless Weight Loss, Vibrant Health, and Boundless Energy. Oxnard, CA: Primal Blueprint Publishing, 2017.

Thompson, Lilian U., Beatrice A. Boucher, Zhen Liu, Michelle Cotterchio, and Nancy Kreiger. "Phytoestrogen Content of Foods Consumed in Canada, Including Isoflavones, Lignans, and Coumestan." Nutrition and Cancer54, no. 2 (2006): 184-201. doi:10.1207/s15327914nc5402_5.

Vine, DF, JCL Mamo, et al. "Dietary oxysterols are incorporated in plasma triglyceriderich lipoproteins, increase their susceptibility to oxidation and increase aortic cholesterol concentration of rabbits." Journal of Lipid Research. 39. (1998): 1995-2004. Print.

Weber,Charles. “The Damaging Effects of Fluoride for Teeth on Thyroid and Brain, and a Cure.” <http://charles_w.tripod.com/fluoride.html.>

"What Is Vitamin D? What Are The Benefits Of Vitamin D?." Medical News Today. Medical News Today, 29 Jan 2013. Web. 

Ying Rong, Li Chen, et al. “Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies.” BMJ 2013; 346;e8539 (Published 7 January 2013) <http://www.bmj.com/content/346/bmj.e8539.>

Zava, David T., Charles M. Dollbaum, and Marilyn Blen. "Estrogen and Progestin Bioactivity of Foods, Herbs, and Spices." Hypertension (High Blood Pressure). Accessed September 03, 2018. http://www.cancersupportivecare.com/estrogenherb.html.

 

Estrogens and Breast Cancer: A Chronology by Carol Ann Rinzler

1929:   The first estrogen (estrone) is isolated and identified

1931:   First American woman given first injection of estrogen

1932:   Estrogen injections produce malignant breast tumors in male laboratory mice

1934:   First use of estrogens to treat symptoms of menopause

1937:   Natural female hormones used to suppress ovulation in laboratory rabbits at Penn State University

            The incidence of breast cancer in the United States is 67 cases per 100,000 (white) women          

1938:   Chemists at Schering Company produce estrogen pills

1940:   The first oral estrogens for ERT go on sale

Scientists at the National Cancer Institute find synthetic estrogen diethylstilbestrol (DES) produces breast tumors in male and female laboratory mice

The leading causes of cancer deaths among American women are cancer of the uterus and cancer of the stomach

The incidence of breast cancer in the United States is 59 cases for every 100,000 women

An American woman’s lifetime risk of breast cancer in 1-in-20

1941:   More than a dozen brands of estrogen are available for treatment of menopausal and menstrual disorders

1944:   Syntex, a pharmaceutical company, created to manufacture and sell synthetic progesterone

1945:   Cancer researcher discover that a chemical’s ability to stimulate unregulated cell growth is one measure of its potential carcinogenicity

1950:   The incidence of breast cancer in the United States is 65 cases for every 100,000 women

An American woman’s lifetime risk of breast cancer in 1-in-15

1951:   Birth control pioneer Margaret Sanger makes first donation to support Gregory Goodman Pincus’ research on chemical contraceptives

            Syntex steroid chemist Carl Djerassi patents nonethindrone, the first effective oral progestin

1955:   More than thirty brands of estrogen products on the market: injectable solutions, pills, ointments, suppositories, and nasal sprays

1956:   G.D. Searle and Planned Parenthood begin trials of the estrogen/progestin birth control pill in Puerto Rico

1957:   FDA approves use of estrogen/progestin combination for medical conditions such as menstrual disorders

1960:   FDA grants permission for Searle to market an estrogen/ progestin product, Enovid-10 as an oral contraceptive

The Merck Index publishes its first warning of a link between estrogen and caner of the breast and reproductive organs

The incidence of breast cancer in the United States is 72 cases for every 100,000 women

An American woman’s lifetime risk of breast cancer is now 1-in-15

1961:   800,000 American women fill their first prescription for an oral contraceptive

1962:   FDA approves a second oral contraceptive, Ortho Pharmaceuticals’ Ortho-Novum

1963:   1.2 million American women are using the Pill

            Robert Wilson meets "Mrs. P.G.," the woman whose use of Enovid-10 keeps her "young" at age fifty

1965:   1-in-4 married American women have used or is using birth control pills

1966:   Robert Wilson publishes Feminine Forever; estimates that in 1967 the number of "sexually restored, post-menopausal women" will pass 14,000

1969:   British Committee on Safety of drugs recommends banning oral contraceptives containing more that 50 mcg estrogen

The First National Conference on Breast Cancer, sponsored by the American Cancer Society (ACS) and the U.S Public Health Service, convenes in Washington D.C.

The ACS predicts 29,000 female breast cancer deaths

The incidence of breast cancer in the United States is 72.5 cases for every 100,000 white; 60.1 cases for every 100,000 black women

1970:   First warning (blood clots) included in package insert for oral contraceptives

            8.5 million American women are using birth control pills; 65 percent of them are "high dose" products with more that 50 mcg of estrogen

The American Medical Association’s Council on Drugs says that estrogen may stimulate existing breast tumors to malignant activity

The incidence of breast cancer in the United States is 74 cases for every 100,000 women

An American woman’s lifetime risk of breast cancer is now 1-in-13

1971:   Synthetic estrogen (DES) reported to cause vaginal cancers in daughter of women who took the drug while pregnant

            Second National Conference on Breast Cancer convenes in Los Angeles

1972:   Breast cancer is now the leading cause of cancer deaths among American women

1973:   10 million American women, including 36 percent of all married women, are using birth control pills

1974:   70 percent of all married American women have a "favorable view" of the Pill

5 million American women are using estrogen to relieve menopausal symptoms

The ACS predicts 90,000 new cases of female breast cancer and 33,000 female breast cancer deaths

1975:   An NCI study shows a six- to elevenfold increase in incidence of breast cancer among women with prior history of benign breast disease who had used the Pill for more than six years

            Four separate studies show an increase as high as 50 percent in the incidence of endometrial cancer among women using estrogen products

1976:   22.3 percent of all fertile American women are using oral contraceptives

            Approximately 6 million women are using ERT

            Study of one doctor’s practice in Kentucky show an overall 30 percent increased risk of breast cancer among women using ERT

1977:   The incidence of breast cancer in the United States is 81 cases for every 100,000 women

1980:   19 percent of American women of childbearing age use the Pill

            17 percent of all birth control pills sold in the United States still contain more than 50 mcg estrogen

A study in two Los Angeles retirement communities shows an 80 percent higher risk of breast cancer among women who take a cumulative lifetime dose of 1,500 mcg estrogen

The incidence of breast cancer in the United States is 90 cases for every 100,000 women

An American woman’s lifetime risk of breast cancer is now 1-in-11

1981:   Research at the University of Southern California finds a significant increase in the incidence of breast cancer among women who use oral contraceptives before a first full-term pregnancy

            Researchers from the National Institute of Health publish study of 1,600 women in twenty-nine cancer centers across the country showing that use of ERT may raise a woman’s risk of breast cancer to nearly seven times higher than normal

1982:   Following publicity about acute effects of oral contraceptives (blood clots, migraine, heart attacks, stroke), the percentage of American married women using the Pill falls to 19.8

1983:   17 million prescriptions are written for estrogen

            Second California study shows that women who use the Pill for more than four years before their first full-term pregnancy or before age twenty-five are four times more likely to develop breast cancer before age forty-five

1984:   New England Journal of Medicine reports a 47 percent higher incidence of breast cancer among 4 million women who used DES while pregnant

The ACS predicts 115,000 new cases of female breast cancer

1985:   11.8 million American women age eighteen to forty-four are using the Pill, the leading reversible method of birth control in the United States; 25 percent of them are using it longer that five years

1986:    Nearly 12.5 million American women age fifteen to forty-four are using the Pill

            FDA approves Estraderm, CIBA Pharmaceutical’s new patch that delivers continue allow doses of estrogen through the skin for post-menopausal ERT

 The ACS predicts 123,000 new cases of female breast cancer and 39,900 deaths

1987:   CASH study shows a more-than-200 percent increase in risk of breast cancer among fifty- to fifty-four-year-old women whose ovaries have been removed or who have a family history of breast cancer and who use ERT

An American woman’s lifetime risk of breast cancer is now 1-in-10

1988:   Approximately 14 million American women age fifteen to forty-four are using the Pill

Nineteen years after the British have acted, the FDA recommends removing from the market all oral contraceptives containing more than 50 mcg estrogen

The ACS predicts 135,000 new cases of female breast cancer and 42,300 deaths

1989:   Nurses Health Study (121,000 married female nurses) show that women currently using oral contraceptives are 60 percent more likely than nonusers to develop breast cancer

            3.5 million American women are using ERT

 The incidence of breast cancer in the America is 105 cases per 100,000 women   

1990: 26 percent of American women of childbearing age are using the Pill

            Nurses Health Study shows that women who use ERT are 30 to 40 percent more likely than nonusers to develop breast cancer

Incidence of ER+ tumors among American women is increasing five times faster than incidence of ER-negative tumors

The ACS predicts 150,000 new cases of female breast cancer and 44,300 deaths

1991:   16 million American women ager fifteen to forty-four are using The Pill; 37 percent of them for five years or longer

            15 percent of all post-menopausal American women are using ERT

A meta-analysis from the U.S. Centers of Disease Control attributes 4, 708 new cases of breast cancer and 1.468 deaths a year to use of ERT

An American woman’s lifetime risk of breast cancer is now 1-in-9

The ACS predicts 175,000 new cases of female breast cancer and 44,500 deaths

1992:   The National Cancer Institute predicts 180,000 new cases of female breast cancer and 46,000 deaths

An American woman’s lifetime risk of breast cancer is now 1-in-8

Chronology continued by Wendy Sellens, DAOM

2000:   The AAFP predicts 182,800 new female cases of breast cancer and 48,800 deaths

2005:   The ACS predicts 211,240 new cases of female invasive breast cancer and 58, 490 of in situ breast cancer and 40,410 deaths

The ACS predicts 1,690 cases of breast cancer in men and 460 deaths

2011:   The ACS predicts 230,480 new cases of female invasive breast cancer and 57,650 of in situ breast cancer and 39,520 deaths.

The ACS predicts 2,140 cases of breast cancer in men and about 1percent of breast cancers  and 450 deaths

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Contact us: 619.723.8769

All information, data, and material contained, presented, or provided on abreastboutique.com is for educational purposes only. It is not to be construed or intended as providing direct and/ or personal medical or legal advice. Decisions you make about your family's healthcare are important and should be made in consultation with a competent medical professional.
Copyright © 2020 a breast boutique | Powered by Shopify
  • american express
  • diners club
  • discover
  • jcb
  • master
  • shopify pay
  • visa